Previous 10 | Next 10 |
DermTech press release (NASDAQ:DMTK): Q4 GAAP EPS of -$0.88 misses by $0.14. Revenue of $3.17M (+51.0% Y/Y) misses by $0.16M. Shares -4.3%. For further details see: DermTech GAAP EPS of -$0.88 misses by $0.14, revenue of $3.17M misses by $0.16M
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of and for the quarter and fiscal year ended December 31, 2021. Fourth Quarter and Full Year 2021 Highl...
DermTech (NASDAQ:DMTK) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close. The consensus EPS Estimate is -$0.75 (-56.3% Y/Y) and the consensus Revenue Estimate is $3.33M (+58.6% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revision...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will present at the following upcoming conferences: Cowen 42nd Annual Health Care Conference Presenti...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the addition of Adelle Walker to the organization as Vice President of Consumer Products. Wal...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to release its fourth quarter and full-year 2021 financial results after the market closes on Tuesday, March 1, 202...
DermTech (NASDAQ: DMTK) and GoodRx (NASDAQ: GDRX) have been huge losers for investors over the last 12 months. In this Motley Fool Live video, recorded on Jan. 12. , Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not it'...
The stock market has had one of its best decades ever, with the SPDR S&P 500 ETF providing 275% returns over the past 10 years. While this performance is extremely impressive, I believe there are two stocks that could outperform the market and provide multibagger returns over the ne...
DMTK has a skin cancer diagnostics test in the market. The company has repeatedly missed earnings, and this time, they also lowered guidance. This sort of steady depletion of shareholder value does not look good for future investments. For further details see: DermTech: ...
BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solution Lineup Integrated telehealth consultations and consumer-friendly testing options help health plans, employers, and government entities execute population heal...